Epitranscriptomic Fingerprinting Offers Promise for Early Cancer Detection

Researchers at the Centre for Genomic Regulation (CRG) in Barcelona have determined that different types of cancer possess unique molecular “fingerprints” detectable in early stages. These fingerprints, found in ribosomal RNA (rRNA), can be identified with high accuracy using portable scanners within hours.

The research challenges the long-held belief that ribosomes have identical blueprints throughout the body. Instead, it unveils a hidden layer of complexity in the form of tiny chemical modifications that vary between tissues, developmental stages, and diseases.

Eva Novoa, lead author of the study published in Molecular Cell, explains, "Our ribosomes are not all the same. They are specialized in different tissues and carry unique signatures that reflect what's happening inside our bodies.” These signatures, termed “epitranscriptomic fingerprints”, are unique to each tissue type.

The team discovered that cancer cells, particularly in lung and testis samples, exhibited “hypomodified” rRNA, consistently losing certain chemical marks. This finding led to the development of an algorithm capable of distinguishing between lung cancer and healthy tissue with near-perfect accuracy, even in early stages.

The research utilized nanopore direct RNA sequencing, a technology that allows for the analysis of rRNA molecules with all their modifications intact. This method can detect cancer's ribosomal fingerprint using minimal amounts of tissue, potentially leading to the development of rapid, highly accurate diagnostic tests. 

While the study shows promise for early cancer detection, the researchers caution that larger studies are needed to validate these biomarkers across diverse populations and cancer types.